A Phase 2 Study of Pembrolizumab Immunotherapy for People With Ultra-Rare Sarcomas

Full Title

Purpose

Researchers are finding out if pembrolizumab immunotherapy can be useful to treat some specific types of sarcomas. The people in this study have ultra-rare sarcomas that have come back, gotten worse, or spread after treatment. The diagnoses included in this study are:

• Pleomorphic liposarcoma
• Perivascular epithelioid cell tumor (PEComa)
• Epithelioid sarcoma
• CIC-rearranged sarcoma
• Sclerosing epithelioid fibrosarcoma

Pembrolizumab takes the brakes off the immune system so immune cells can find and hopefully attack cancer cells. It is given intravenously (by vein).

Contact

For more information about this study or to see if you can join, please call Dr. Robert Maki’s office at 646-888-5059.